Physician profile
Scott M Cherry
NPI 1699895441
$8,137.49
in general payments reported to CMS, 2019-2025
44 companies · $976 in 2025
The $976 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $727 · 2021: $832 · 2022: $1,293 · 2023: $1,427 · 2024: $1,534 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,936.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.04 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $1,017.53 | 2019-2024 | |
| Biogen, INC. | $734.89 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Celgene Corporation | $584.65 | 2021-2025 | Zeposia |
| Pfizer INC. | $437.16 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $343.46 | 2019-2024 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Sk Life Science, INC. | $338.99 | 2020-2025 | |
| Argenx US, INC. | $335.14 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Emd Serono, INC. | $281.97 | 2019-2024 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $278.72 | 2020-2025 | Qelbree, Oxtellar Xr |
| Acadia Pharmaceuticals INC | $252.29 | 2019-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $240.74 | 2019-2022 | |
| Ucb, INC. | $234.29 | 2019-2024 | Briviact |
| Teva Pharmaceuticals USA, INC. | $230.07 | 2019-2023 | Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $172.13 | 2019-2024 | Ultomiris |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.